<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Neuropsychopharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Int. J. Neuropsychopharmacol</journal-id><journal-id journal-id-type="publisher-id">PNP</journal-id><journal-title-group><journal-title>The International Journal of Neuropsychopharmacology</journal-title></journal-title-group><issn pub-type="ppub">1461-1457</issn><issn pub-type="epub">1469-5111</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24787143</article-id><article-id pub-id-type="pmc">4162519</article-id><article-id pub-id-type="doi">10.1017/S1461145714000546</article-id><article-id pub-id-type="pii">S1461145714000546</article-id><article-id pub-id-type="publisher-id">00054</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults</article-title><alt-title alt-title-type="left-running">R. S. McIntyre et al.</alt-title><alt-title alt-title-type="right-running">Vortioxetine and cognitive function in depressed adults</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>McIntyre</surname><given-names>Roger S.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Lophaven</surname><given-names>S&#x000f8;ren</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Olsen</surname><given-names>Christina K.</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Mood Disorders Psychopharmacology Unit</addr-line>, <institution>University Health Network, University of Toronto</institution>, <addr-line>Toronto, ON</addr-line>, <country>Canada</country></aff><aff id="aff2"><label>2</label><institution>H. Lundbeck A/S</institution>, <addr-line>Copenhagen</addr-line>, <country>Denmark</country></aff><author-notes><corresp id="cor1"><addr-line>Address for correspondence: R. S. McIntyre, Department of Psychiatry and Pharmacology, Mood Disorders Psychopharmacology Unit</addr-line>, <institution>University of Toronto, University Health Network</institution>, <addr-line>399 Bathurst Street, Toronto, ON, M5T 2S8</addr-line>, <country>Canada</country>. <italic>Tel</italic>.: <phone>+1 -416-603-5279</phone><italic>Fax</italic>: <fax>+1-416-603-5368</fax><italic>Email</italic>: <email>roger.mcintyre@uhn.ca</email></corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>30</day><month>4</month><year>2014</year></pub-date><volume>17</volume><issue>10</issue><fpage>1557</fpage><lpage>1567</lpage><history><date date-type="received"><day>24</day><month>1</month><year>2014</year></date><date date-type="rev-request"><day>17</day><month>2</month><year>2014</year></date><date date-type="rev-recd"><day>26</day><month>2</month><year>2014</year></date><date date-type="accepted"><day>20</day><month>3</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; CINP 2014</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>CINP</copyright-holder><license license-type="open-access"><license-p><!--CREATIVE COMMONS-->The online version of this article is published within an Open Access environment subject to the conditions of the Creative Commons Attribution licence <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link></license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="S1461145714000546a.pdf"/><abstract abstract-type="normal"><p>The efficacy of vortioxetine 10 and 20&#x000a0;mg/d <italic>vs.</italic> placebo on cognitive function and depression in adults with recurrent moderate-to-severe major depressive disorder (MDD) was evaluated. Patients (18&#x02013;65&#x000a0;yr, <italic>N</italic>&#x000a0;=&#x000a0;602) were randomized (1:1:1) to vortioxetine 10 or 20&#x000a0;mg/d or placebo for 8 wk in a double-blind multi-national study. Cognitive function was assessed with objective neuropsychological tests of executive function, processing speed, attention and learning and memory, and a subjective cognitive measure. The primary outcome measure was change from baseline to week 8 in a composite z-score comprising the Digit Symbol Substitution Test (DSST) and Rey Auditory Verbal Learning Test (RAVLT) scores. Depressive symptoms were assessed using the Montgomery-&#x000c5;sberg Depression Rating Scale (MADRS). In the pre-defined primary efficacy analysis, both doses of vortioxetine were significantly better than placebo, with mean treatment differences <italic>vs.</italic> placebo of 0.36 (vortioxetine 10&#x000a0;mg, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001) and 0.33 (vortioxetine 20&#x000a0;mg, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001) on the composite cognition score. Significant improvement <italic>vs.</italic> placebo was observed for vortioxetine on most of the secondary objectives and subjective patient-reported cognitive measures. The differences to placebo in the MADRS total score at week 8 were &#x02212;4.7 (10&#x000a0;mg: <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001) and &#x02212;6.7 (20&#x000a0;mg: <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001). Path and subgroup analyses indicate that the beneficial effect of vortioxetine on cognition is largely a direct treatment effect. No safety concern emerged with vortioxetine. Vortioxetine significantly improved objective and subjective measures of cognitive function in adults with recurrent MDD and these effects were largely independent of its effect on improving depressive symptoms.</p></abstract><kwd-group><title>Key words</title><kwd>Cognitive function</kwd><kwd>path analysis</kwd><kwd>recurrent major depression</kwd><kwd>tolerability</kwd></kwd-group><counts><fig-count count="2"/><table-count count="3"/><ref-count count="44"/><page-count count="11"/></counts></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>Major depressive disorder (MDD) is a common mental disorder often associated with deficits in cognitive function (see McIntyre et al., <xref rid="ref24" ref-type="bibr">2013</xref> for a recent review). The Diagnostic and Statistical Manual 5 (DSM-5) lists impairment in cognition (i.e. diminished ability to think or concentrate or indecisiveness) as a criterion item in the diagnosis of a major depressive episode (MDE). In addition to being a reason for frequent subjective complaints, objective deficits in measures of executive function, processing speed, attention, learning and memory during, and after resolution of an MDE have been reported (Porter et al., <xref rid="ref32" ref-type="bibr">2007</xref>; Hammar and Ardal, <xref rid="ref14" ref-type="bibr">2009</xref>; Baune et al., <xref rid="ref3" ref-type="bibr">2010</xref>).</p><p>The estimated annual costs attributable to MDD are $83 billion in the US, with indirect costs due to decreased psychosocial function (notably workforce performance) being a major contributor (Greenberg et al., <xref rid="ref12" ref-type="bibr">2003</xref>). Preliminary evidence suggests that cognitive dysfunction is an important mediator of functional impairment (i.e. workplace performance) in individuals with MDD (Buist-Bouwman et al., <xref rid="ref7" ref-type="bibr">2008</xref>). Moreover, it has been proposed that improvement in cognitive function significantly influences functional recovery from an MDE (Jaeger et al., <xref rid="ref18" ref-type="bibr">2006</xref>; Greer et al., <xref rid="ref13" ref-type="bibr">2010</xref>).</p><p>Vortioxetine (1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine-hydrobromide, Lu AA21004) is a novel antidepressant that has demonstrated efficacy in doses up to 20&#x000a0;mg/d in short-term studies of 6&#x02013;8&#x000a0;wk duration in adult patients with MDD (Alvarez et al., <xref rid="ref1" ref-type="bibr">2012</xref>; Henigsberg et al., <xref rid="ref16" ref-type="bibr">2012</xref>; Boulenger et al., <xref rid="ref6" ref-type="bibr">2014</xref>). Its principal mode of action is hypothesized to occur via the combination of a direct effect on receptor activity and serotonin (5-HT) reuptake inhibition (Bang-Andersen et al., <xref rid="ref2" ref-type="bibr">2011</xref>; Westrich et al., <xref rid="ref41" ref-type="bibr">2012</xref>). <italic>In vitro</italic> studies in recombinant cell lines show that vortioxetine is a 5-HT<sub>3</sub>, 5-HT<sub>1D</sub>, and 5-HT<sub>7</sub> receptor antagonist, 5-HT<sub>1B</sub> receptor partial agonist, 5-HT<sub>1A</sub> receptor agonist, and a 5-HT transporter inhibitor (Bang-Andersen et al., <xref rid="ref2" ref-type="bibr">2011</xref>; M&#x000f8;rk et al., <xref rid="ref25" ref-type="bibr">2012</xref>; Westrich et al., <xref rid="ref41" ref-type="bibr">2012</xref>).</p><p>The efficacy of vortioxetine 5&#x000a0;mg/d on both depressive symptoms and cognitive function has been demonstrated in a placebo-controlled 8&#x000a0;wk study with duloxetine as active reference in patients aged &#x02a7e;65 yr with MDD (Katona et al., <xref rid="ref20" ref-type="bibr">2012</xref>). That study was designed to compare the effect of vortioxetine to that of placebo on depressive symptom severity, with cognitive function as a secondary efficacy outcome.</p><p>To our knowledge, only one large study has primarily aimed to compare the efficacy of a conventional antidepressant <italic>vs.</italic> placebo on cognition (Raskin et al., <xref rid="ref33" ref-type="bibr">2007</xref>). That study reported that duloxetine demonstrated significantly greater improvement in a composite cognitive score (mediated largely by improvement in verbal learning and memory) than placebo in elderly patients (aged &#x02a7e;65&#x000a0;yr) with recurrent MDD. Studies are challenged by the heterogeneity of cognitive dysfunction and few studies have evaluated the effect of antidepressants on non-emotional, objectively measured cognitive performance in non-elderly, adults with MDD, and they generally have a small sample size, are not placebo-controlled and assess treatment effect compared to baseline (Biringer et al., <xref rid="ref4" ref-type="bibr">2009</xref>; McIntyre et al., <xref rid="ref24" ref-type="bibr">2013</xref>).</p><p>Herein, we primarily aimed to evaluate the efficacy of vortioxetine 10 and 20&#x000a0;mg/d <italic>vs.</italic> placebo on cognitive function in adults (aged &#x02a7d;65&#x000a0;yr) with recurrent MDD during a depressive episode of moderate severity or greater. The primary efficacy endpoint was a composite cognition score comprising the Digit Symbol Substitution Test (DSST) and the Rey Auditory Verbal Learning Test (RAVLT). These and homologous tests address key cognitive domains shown to be impaired in patients with depression and have demonstrated clinical sensitivity in MDD in the elderly population (Raskin et al., <xref rid="ref33" ref-type="bibr">2007</xref>; Katona et al., <xref rid="ref20" ref-type="bibr">2012</xref>). The present study aimed to extend the investigation to the adult MDD population including a broader assessment of objective and subjective measures of cognition in addition to depressive symptoms, safety and tolerability as secondary outcomes.</p></sec><sec sec-type="methods" id="sec2"><title>Method</title><sec id="sec2-1" sec-type="subjects"><title>Patients</title><p>This double-blind, randomized, fixed-dose, placebo-controlled, study included patients from 79 psychiatric inpatient and outpatient settings in 12 countries (Australia, Canada, Finland, France, Germany, Latvia, Mexico, Serbia, Slovakia, South Africa, Ukraine, and the USA) from December 2011 to May 2013. Patients were recruited by advertisements in 9 countries (Australia, Canada, Finland, France, Germany, Latvia, Mexico, South Africa, and the USA) or via referrals from general practitioners. The study was conducted in accordance with the principles of <italic>Good Clinical Practice</italic> (ICH, <xref rid="ref17" ref-type="bibr">1996</xref>) and the <italic>Declaration of Helsinki</italic> (WMA, <xref rid="ref42" ref-type="bibr">2008</xref>). Local research ethics committees approved the trial design, and all eligible patients provided written informed consent before participating.</p></sec><sec id="sec2-2"><title>Randomization and treatment</title><p>Eligible patients were assigned to double-blind treatment according to a randomization list that was computer generated by H. Lundbeck A/S. The details of the randomization series were contained in a set of sealed opaque envelopes. At each site, sequentially enrolled patients were assigned the lowest randomization number available in blocks of 6 using an interactive voice/web response system. All investigators, trial personnel and patients were blinded to treatment assignment for the duration of the study. The randomization code was not broken for any patient during the study.</p></sec><sec id="sec2-3"><title>Study procedures</title><p>After a screening period of up to 10&#x000a0;d, 602 eligible patients were randomized (1:1:1) to vortioxetine 10&#x000a0;mg/d, vortioxetine 20&#x000a0;mg/d, or placebo for 8&#x000a0;wk of double-blind treatment. Patients in the vortioxetine 20&#x000a0;mg/d group received vortioxetine 10&#x000a0;mg/d in week 1 and 20&#x000a0;mg/d from weeks 2 to 8. Patients were seen at baseline, and weeks 1, 4, and 8. Patients who withdrew prior to study completion were evaluated at the earliest possible date after withdrawal. A safety follow-up contact was scheduled for 4 wk after completion of the treatment period or after withdrawal from the study. Study medications were given as capsules of identical appearance. Following randomization, patients were instructed to take one capsule per day, orally, preferably in the morning.</p><p>Patients aged &#x02a7e;18 and &#x02a7d;65 yr, with a primary diagnosis of recurrent MDD according to DSM IV-TR criteria, a current MDE &#x02a7e;3 months&#x02019; duration (confirmed using the Mini International Neuropsychiatric Interview (Lecrubier et al., <xref rid="ref22" ref-type="bibr">1997</xref>)) and a Montgomery-&#x000c5;sberg Depression Rating Scale (MADRS) total score &#x02a7e;26 at screening and baseline visits were eligible for inclusion in the study. Patient inclusion and exclusion criteria for this study were similar to other studies in MDD. For patient exclusion criteria, see the Supplementary Material. In brief, patients were excluded if they were taking psychotropic drugs within 2 wk prior to baseline or during the study, including reversible or irreversible monoamine oxidase inhibitors, serotonin reuptake inhibitors (fluoxetine within 5&#x000a0;wk), serotonin noradrenaline reuptake inhibitors, tricyclic antidepressants, psychoactive herbal remedies, any drug used for augmentation of antidepressant action or any other antidepressant drugs, oral antipsychotic and anti-manic drugs, or dopamine antagonists, or any anxiolytics.</p></sec><sec id="sec2-4"><title>Outcome measures</title><p>The effect of vortioxetine (10 or 20&#x000a0;mg/d) <italic>vs.</italic> placebo on cognitive function was assessed using the following neuropsychological tests: DSST (executive function, speed of processing, attention), RAVLT (learning, memory), Trail Making Test A/B (TMT-A: speed of processing; TMT-B: executive function), Stroop test (congruent and incongruent: executive function); Simple reaction time task (SRT: speed of processing), and the Choice reaction time task (CRT: attention) at baseline, week 1 and week 8. In addition, the patient-reported cognitive measure, Perceived Deficits Questionnaire (PDQ) comprising four subscales: attention/concentration, prospective memory, planning/organization, and retrospective memory was assessed at baseline and week 8. For details of these assessments, see the Supplementary Material.</p><p>The MADRS and Clinical Global Impression &#x02013; Severity of Illness (CGI-S) were assessed at baseline, and weeks 1, 4, and 8, and the Clinical Global Impression &#x02013; Global Improvement (CGI-I) at weeks 1, 4, and 8. The MADRS was administered after the neuropsychological tests and before the Columbia-Suicide Severity Rating Scale (C-SSRS) and CGI scales.</p></sec><sec id="sec2-5"><title>Statistical analysis</title><p>Safety analyses were based on the <italic>all-patients-treated set</italic> (APTS), comprising all randomized patients who took at least one dose of study medication. Efficacy analyses were based on a modified <italic>intention-to-treat set</italic> &#x02013; the <italic>full-analysis set</italic> (FAS), comprising all patients in the APTS who had at least one valid post-baseline assessment of the primary efficacy variable (the DSST and the RAVLT [acquisition and delayed recall]).</p><p>The primary efficacy analysis was the change from baseline to week 8 in the composite z-score defined as the equally weighted sum of the z-scores in the DSST and RAVLT, thus assessing a broad range of cognitive domains, including executive function, attention, processing speed, and learning and memory. The DSST score was assigned a weight of 0.5, and the two subtest scores of the RAVLT (acquisition [learning] and delayed recall [memory]) were each assigned a weight of 0.25. The composite z-score is used for the first time in this study and is based on <italic>post-hoc</italic> analysis of the vortioxetine study of elderly patients with MDD (Katona et al., <xref rid="ref20" ref-type="bibr">2012</xref>). Based on a Missing-at-Random assumption, these analyses were performed using all available data from all patients in the FAS. The model included treatment and center as fixed factors. The baseline composite z-score was used as a covariate. Interactions between visit and treatment and baseline composite z-score were also included in the model. An unstructured covariance structure was used to model the within-patient variation. For endpoints that occurred after the pre-specified statistical testing procedure was stopped or that were outside the testing procedure, nominal p-values with no adjustment for multiplicity were reported. The phrasing &#x02018;separation from placebo&#x02019; is used to describe findings with <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05. Efficacy analyses that were not multiplicity-controlled were considered secondary. For details of the testing hierarchy and descriptions of key secondary and secondary analyses, multiple regression analyses [path analysis] and <italic>post-hoc</italic> sub-group analyses, see the Supplementary Material.</p><p>The sample size calculation was based on an overall significance level of 5% by having 2.5% within each dose in order to adjust for multiplicity. For the primary endpoint (composite z-score), the treatment difference to placebo for each vortioxetine dose at week 8 was assumed to be 0.25, based on the results with elderly patients (Katona et al., <xref rid="ref20" ref-type="bibr">2012</xref>). A total of 600 patients (200 per arm) were needed for the mixed model for repeated measures (MMRM) using all available data to provide a power of &#x02248;90% for finding at least one dose significant, and a power of &#x02248;85% for finding a specific dose significant, assuming a 20% withdrawal rate.</p></sec><sec id="sec2-6"><title>Safety and tolerability assessments</title><p>Starting at baseline, patients were asked a non-leading question at each visit (such as, &#x02018;<italic>how do you feel?&#x02019;</italic>). All adverse events (AEs), either observed by the investigator or reported spontaneously by the patient, were recorded together with vital signs. Qualified personnel coded AEs using the lowest level term according to MedDRA, version 15.1. The incidence of individual AEs was compared between treatment groups using Fisher's exact test. Clinical safety laboratory tests, weight, body mass index (BMI), electrocardiographs (ECGs), and physical examination findings were also evaluated. Potential relationships between study drug and suicidality were assessed using the C-SSRS (US FDA, <xref rid="ref40" ref-type="bibr">2010</xref>). As a <italic>post-hoc</italic> analysis, the safety database was searched at the verbatim (investigator's term) level for possible suicide-related AEs (Laughren, <xref rid="ref21" ref-type="bibr">2006</xref>).</p></sec></sec><sec sec-type="results" id="sec3"><title>Results</title><sec id="sec3-1"><title>Study sample</title><p>The APTS included 598 patients after the exclusion of 4 patients who did not take any study medication (see Supplementary Material, Fig. S1). With a mean baseline MADRS total score of 31.6, patients were moderately to severely depressed. There were no clinically relevant differences between treatment groups in demographic or clinical characteristics at baseline (<xref ref-type="table" rid="tab01">Table 1</xref>).
<table-wrap id="tab01" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Demographics and baseline clinical characteristics (APTS)</p></caption><alternatives><graphic xlink:href="S1461145714000546_tab1"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Placebo (<italic>n</italic>&#x000a0;=&#x000a0;196)</th><th align="left" rowspan="1" colspan="1">Vortioxetine 10&#x000a0;mg (<italic>n</italic>&#x000a0;=&#x000a0;195)</th><th align="left" rowspan="1" colspan="1">Vortioxetine 20&#x000a0;mg (<italic>n</italic>&#x000a0;=&#x000a0;207)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Women <italic>n</italic> (%)</td><td rowspan="1" colspan="1">129 (65.8%)</td><td rowspan="1" colspan="1">134 (68.7%)</td><td rowspan="1" colspan="1">133 (64.3%)</td></tr><tr><td rowspan="1" colspan="1">Mean age&#x000a0;&#x000b1;&#x000a0;<sc>s.d.</sc> (yr)</td><td rowspan="1" colspan="1">45.6&#x000a0;&#x000b1;&#x000a0;12.1</td><td rowspan="1" colspan="1">45.4&#x000a0;&#x000b1;&#x000a0;12.2</td><td rowspan="1" colspan="1">46.1&#x000a0;&#x000b1;&#x000a0;11.8</td></tr><tr><td rowspan="1" colspan="1">Range (yr)</td><td rowspan="1" colspan="1">19&#x02013;65</td><td rowspan="1" colspan="1">18&#x02013;65</td><td rowspan="1" colspan="1">18&#x02013;65</td></tr><tr><td rowspan="1" colspan="1">Caucasian (%)</td><td rowspan="1" colspan="1">95.9%</td><td rowspan="1" colspan="1">93.8%</td><td rowspan="1" colspan="1">93.7%</td></tr><tr><td rowspan="1" colspan="1">Median length of current MDE (wk)</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">19</td></tr><tr><td rowspan="1" colspan="1">Previous MDEs, mean&#x000a0;&#x000b1;&#x000a0;<sc>s.d.</sc> (<italic>n</italic>)</td><td rowspan="1" colspan="1">2.4&#x000a0;&#x000b1;&#x000a0;2.0</td><td rowspan="1" colspan="1">2.3&#x000a0;&#x000b1;&#x000a0;1.7</td><td rowspan="1" colspan="1">2.6&#x000a0;&#x000b1;&#x000a0;2.1</td></tr><tr><td rowspan="1" colspan="1">Range (<italic>n</italic>)</td><td rowspan="1" colspan="1">1&#x02013;11</td><td rowspan="1" colspan="1">1&#x02013;11</td><td rowspan="1" colspan="1">1&#x02013;13</td></tr><tr><td rowspan="1" colspan="1">Assessment scores (FAS), mean&#x000a0;&#x000b1;&#x000a0;<sc>s.d.</sc></td><td rowspan="1" colspan="1">(<italic>n</italic>&#x000a0;=&#x000a0;194)</td><td rowspan="1" colspan="1">(<italic>n</italic>&#x000a0;=&#x000a0;193)</td><td rowspan="1" colspan="1">(<italic>n</italic>&#x000a0;=&#x000a0;204)</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;MADRS total score</td><td rowspan="1" colspan="1">31.3&#x000a0;&#x000b1;&#x000a0;3.8</td><td rowspan="1" colspan="1">31.6&#x000a0;&#x000b1;&#x000a0;3.8</td><td rowspan="1" colspan="1">31.7&#x000a0;&#x000b1;&#x000a0;3.5</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;CGI-S</td><td rowspan="1" colspan="1">4.55&#x000a0;&#x000b1;&#x000a0;0.63</td><td rowspan="1" colspan="1">4.60&#x000a0;&#x000b1;&#x000a0;0.62</td><td rowspan="1" colspan="1">4.62&#x000a0;&#x000b1;&#x000a0;0.58</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;DSST<sub>correct symbols</sub></td><td rowspan="1" colspan="1">42.4&#x000a0;&#x000b1;&#x000a0;14</td><td rowspan="1" colspan="1">42.0&#x000a0;&#x000b1;&#x000a0;13</td><td rowspan="1" colspan="1">41.6&#x000a0;&#x000b1;&#x000a0;13</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;RAVLT<sub>acquisition</sub></td><td rowspan="1" colspan="1">22.1&#x000a0;&#x000b1;&#x000a0;6</td><td rowspan="1" colspan="1">22.3&#x000a0;&#x000b1;&#x000a0;6</td><td rowspan="1" colspan="1">22.6&#x000a0;&#x000b1;&#x000a0;6</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;RAVLT<sub>delayed recall</sub></td><td rowspan="1" colspan="1">5.70&#x000a0;&#x000b1;&#x000a0;2.8</td><td rowspan="1" colspan="1">5.76&#x000a0;&#x000b1;&#x000a0;2.8</td><td rowspan="1" colspan="1">6.05&#x000a0;&#x000b1;&#x000a0;3.1</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;PDQ<sub>total score</sub></td><td rowspan="1" colspan="1">39.8&#x000a0;&#x000b1;&#x000a0;12</td><td rowspan="1" colspan="1">41.4&#x000a0;&#x000b1;&#x000a0;12</td><td rowspan="1" colspan="1">41.1&#x000a0;&#x000b1;&#x000a0;12</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;PDQ<sub>attention/concentration</sub></td><td rowspan="1" colspan="1">11.9&#x000a0;&#x000b1;&#x000a0;3.3</td><td rowspan="1" colspan="1">12.4&#x000a0;&#x000b1;&#x000a0;3.4</td><td rowspan="1" colspan="1">12.4&#x000a0;&#x000b1;&#x000a0;3.2</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;PDQ<sub>prospective memory</sub></td><td rowspan="1" colspan="1">7.32&#x000a0;&#x000b1;&#x000a0;3.2</td><td rowspan="1" colspan="1">7.85&#x000a0;&#x000b1;&#x000a0;3.3</td><td rowspan="1" colspan="1">7.61&#x000a0;&#x000b1;&#x000a0;3.4</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;PDQ<sub>planning/organization</sub></td><td rowspan="1" colspan="1">11.6&#x000a0;&#x000b1;&#x000a0;3.7</td><td rowspan="1" colspan="1">11.6&#x000a0;&#x000b1;&#x000a0;3.7</td><td rowspan="1" colspan="1">11.8&#x000a0;&#x000b1;&#x000a0;3.9</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;PDQ<sub>retrospective memory</sub></td><td rowspan="1" colspan="1">8.98&#x000a0;&#x000b1;&#x000a0;3.8</td><td rowspan="1" colspan="1">9.53&#x000a0;&#x000b1;&#x000a0;3.6</td><td rowspan="1" colspan="1">9.28&#x000a0;&#x000b1;&#x000a0;4.0</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;TMT-A (s)</td><td rowspan="1" colspan="1">48.7&#x000a0;&#x000b1;&#x000a0;25</td><td rowspan="1" colspan="1">46.5&#x000a0;&#x000b1;&#x000a0;24</td><td rowspan="1" colspan="1">46.2&#x000a0;&#x000b1;&#x000a0;27</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;TMT-B (s)</td><td rowspan="1" colspan="1">105&#x000a0;&#x000b1;&#x000a0;53</td><td rowspan="1" colspan="1">102&#x000a0;&#x000b1;&#x000a0;52</td><td rowspan="1" colspan="1">103&#x000a0;&#x000b1;&#x000a0;52</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Stroop<sub>congruent</sub> (s)</td><td rowspan="1" colspan="1">50.0&#x000a0;&#x000b1;&#x000a0;25</td><td rowspan="1" colspan="1">49.6&#x000a0;&#x000b1;&#x000a0;25</td><td rowspan="1" colspan="1">50.0&#x000a0;&#x000b1;&#x000a0;28</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Stroop<sub>incongruent</sub> (s)</td><td rowspan="1" colspan="1">85.7&#x000a0;&#x000b1;&#x000a0;39</td><td rowspan="1" colspan="1">85.0&#x000a0;&#x000b1;&#x000a0;41</td><td rowspan="1" colspan="1">83.6&#x000a0;&#x000b1;&#x000a0;41</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;SRT (log<sub>10</sub> ms)</td><td rowspan="1" colspan="1">2.64&#x000a0;&#x000b1;&#x000a0;0.20</td><td rowspan="1" colspan="1">2.64&#x000a0;&#x000b1;&#x000a0;0.20</td><td rowspan="1" colspan="1">2.63&#x000a0;&#x000b1;&#x000a0;0.20</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;CRT (log<sub>10</sub> ms)</td><td rowspan="1" colspan="1">2.78&#x000a0;&#x000b1;&#x000a0;0.14</td><td rowspan="1" colspan="1">2.78&#x000a0;&#x000b1;&#x000a0;0.14</td><td rowspan="1" colspan="1">2.78&#x000a0;&#x000b1;&#x000a0;0.14</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>APTS, all patients treated set; CGI-S, Clinical Global Impression &#x02013; Severity; CRT, choice reaction time task; DSST, Digit Symbol Substitution Test; FAS, full-analysis set; MADRS, Montgomery-&#x000c5;sberg Depression Rating Scale; MDE, major depressive episode; PDQ, Perceived Deficits Questionnaire; RAVLT, Rey Auditory Verbal Learning Test; <sc>s.d.</sc>, standard deviation; SRT, simple reaction time task; TMT, trail making test.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec3-2"><title>Withdrawals from the study</title><p>There were no differences to placebo in either of the active treatment groups in the proportion of patients who withdrew from the study. The proportions of patients who withdrew during treatment because of treatment-emergent AEs were 4.1% (placebo), 2.6% (vortioxetine 10&#x000a0;mg) and 4.3% (vortioxetine 20&#x000a0;mg). Approximately 87% of the patients in each group received study medication for 50&#x02013;63&#x000a0;d. The total exposure accrued in each treatment group was approximately 28 patient-yr.</p></sec></sec><sec id="sec4"><title>Efficacy</title><sec id="sec4-1"><title>Primary efficacy endpoint</title><p>In the pre-defined primary efficacy analysis, both doses of vortioxetine were significantly superior <italic>vs.</italic> placebo in mean change from baseline to week 8 in the composite z-score (FAS, MMRM), with a mean treatment difference to placebo of 0.36 [95% CI: 0.22;0.50] (vortioxetine 10&#x000a0;mg, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001) and 0.33 [95% CI: 0.19; 0.47] (vortioxetine 20&#x000a0;mg, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001) (<xref ref-type="table" rid="tab02">Table 2</xref>).
<table-wrap id="tab02" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Efficacy analyses, change from baseline to week 8, difference to placebo (mean&#x000b1;<sc>s.e.</sc> [95% CI]) (FAS, MMRM)</p></caption><alternatives><graphic xlink:href="S1461145714000546_tab2"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><thead><tr><th rowspan="2" valign="bottom" colspan="1"/><th align="left" rowspan="1" colspan="1">Placebo (<italic>n</italic>&#x000a0;=&#x000a0;194)</th><th colspan="3" align="left" rowspan="1">Vortioxetine 10&#x000a0;mg (<italic>n</italic>&#x000a0;=&#x000a0;193)</th><th colspan="3" align="left" rowspan="1">Vortioxetine 20&#x000a0;mg (<italic>n</italic>&#x000a0;=&#x000a0;204)</th></tr><tr><th align="left" rowspan="1" colspan="1">&#x00394; baseline</th><th align="left" rowspan="1" colspan="1">&#x00394; baseline</th><th align="left" rowspan="1" colspan="1">&#x00394; placebo</th><th align="left" rowspan="1" colspan="1"><italic>p</italic>-value</th><th align="left" rowspan="1" colspan="1">&#x00394; baseline</th><th align="left" rowspan="1" colspan="1">&#x00394; placebo</th><th align="left" rowspan="1" colspan="1"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="8" rowspan="1">Primary endpoint</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Composite z- score (DSST/RAVLT<sub>acq</sub>/RAVLT<sub>delay</sub>)</td><td rowspan="1" colspan="1">&#x02212;0.24&#x000a0;&#x000b1;&#x000a0;0.05<xref ref-type="table-fn" rid="tfn2_1"><sup>a</sup></xref></td><td rowspan="1" colspan="1">0.13&#x000a0;&#x000b1;&#x000a0;0.05</td><td rowspan="1" colspan="1">0.36&#x000a0;&#x000b1;&#x000a0;0.07 [0.22; 0.50]</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">0.10&#x000a0;&#x000b1;&#x000a0;0.05</td><td rowspan="1" colspan="1">0.33&#x000a0;&#x000b1;&#x000a0;0.07 [0.19; 0.47]</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" colspan="8" rowspan="1">Key secondary endpoints</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;DSST<sub>correct symbols</sub></td><td rowspan="1" colspan="1">4.83&#x000a0;&#x000b1;&#x000a0;0.63</td><td rowspan="1" colspan="1">9.03&#x000a0;&#x000b1;&#x000a0;0.63</td><td rowspan="1" colspan="1">4.20&#x000a0;&#x000b1;&#x000a0;0.87 [2.50; 5.90]</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">9.09&#x000a0;&#x000b1;&#x000a0;0.61</td><td rowspan="1" colspan="1">4.26&#x000a0;&#x000b1;&#x000a0;0.86 [2.57; 5.94]</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;RAVLT<sub>acquisition</sub></td><td rowspan="1" colspan="1">3.06&#x000a0;&#x000b1;&#x000a0;0.34</td><td rowspan="1" colspan="1">4.08&#x000a0;&#x000b1;&#x000a0;0.34</td><td rowspan="1" colspan="1">1.02&#x000a0;&#x000b1;&#x000a0;0.46 [0.11; 1.93]</td><td rowspan="1" colspan="1">0.029</td><td rowspan="1" colspan="1">3.65&#x000a0;&#x000b1;&#x000a0;0.33</td><td rowspan="1" colspan="1">0.59&#x000a0;&#x000b1;&#x000a0;0.46 [&#x02212;0.31; 1.50]</td><td rowspan="1" colspan="1">0.199</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;RAVLT<sub>delayed recall</sub></td><td rowspan="1" colspan="1">0.91&#x000a0;&#x000b1;&#x000a0;0.18</td><td rowspan="1" colspan="1">1.63&#x000a0;&#x000b1;&#x000a0;0.18</td><td rowspan="1" colspan="1">0.71&#x000a0;&#x000b1;&#x000a0;0.24 [0.24; 1.19]</td><td rowspan="1" colspan="1">0.003</td><td rowspan="1" colspan="1">1.56&#x000a0;&#x000b1;&#x000a0;0.17</td><td rowspan="1" colspan="1">0.65&#x000a0;&#x000b1;&#x000a0;0.24 [0.17; 1.12]</td><td rowspan="1" colspan="1">0.007</td></tr><tr><td align="left" colspan="8" rowspan="1">Secondary cognition endpoints</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;TMT-A (s)</td><td rowspan="1" colspan="1">&#x02212;7.1&#x000a0;&#x000b1;&#x000a0;1.0</td><td rowspan="1" colspan="1">&#x02212;10.8&#x000a0;&#x000b1;&#x000a0;1.0</td><td rowspan="1" colspan="1">&#x02212;3.8&#x000a0;&#x000b1;&#x000a0;1.4 [&#x02212;6.4; &#x02212;1.1]</td><td rowspan="1" colspan="1">0.006</td><td rowspan="1" colspan="1">&#x02212;10.9&#x000a0;&#x000b1;&#x000a0;1.0</td><td rowspan="1" colspan="1">&#x02212;3.8&#x000a0;&#x000b1;&#x000a0;1.4 [&#x02212;6.5; &#x02212;1.1]</td><td rowspan="1" colspan="1">0.005</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;TMT-B (s)</td><td rowspan="1" colspan="1">&#x02212;13.8&#x000a0;&#x000b1;&#x000a0;2.0</td><td rowspan="1" colspan="1">&#x02212;21.4&#x000a0;&#x000b1;&#x000a0;2.0</td><td rowspan="1" colspan="1">&#x02212;7.6&#x000a0;&#x000b1;&#x000a0;2.7 [&#x02212;12.9; &#x02212;2.2]</td><td rowspan="1" colspan="1">0.006</td><td rowspan="1" colspan="1">&#x02212;22.8&#x000a0;&#x000b1;&#x000a0;1.9</td><td rowspan="1" colspan="1">&#x02212;9.0&#x000a0;&#x000b1;&#x000a0;2.7 [&#x02212;14.3; &#x02212;3.7]</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;SRT (log<sub>10</sub> ms)</td><td rowspan="1" colspan="1">&#x02212;0.007&#x000a0;&#x000b1;&#x000a0;0.009</td><td rowspan="1" colspan="1">&#x02212;0.053&#x000a0;&#x000b1;&#x000a0;0.009</td><td rowspan="1" colspan="1">&#x02212;0.046&#x000a0;&#x000b1;&#x000a0;0.012 [&#x02212;0.069; &#x02212;0.022]</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">&#x02212;0.037&#x000a0;&#x000b1;&#x000a0;0.009</td><td rowspan="1" colspan="1">&#x02212;0.029&#x000a0;&#x000b1;&#x000a0;0.012 [&#x02212;0.053; &#x02212;0.0055]</td><td rowspan="1" colspan="1">0.016</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;CRT (log<sub>10</sub> ms)</td><td rowspan="1" colspan="1">&#x02212;0.015&#x000a0;&#x000b1;&#x000a0;0.007</td><td rowspan="1" colspan="1">&#x02212;0.046&#x000a0;&#x000b1;&#x000a0;0.007</td><td rowspan="1" colspan="1">&#x02212;0.032&#x000a0;&#x000b1;&#x000a0;0.009 [&#x02212;0.049; &#x02212;0.014]</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">&#x02212;0.023&#x000a0;&#x000b1;&#x000a0;0.006</td><td rowspan="1" colspan="1">&#x02212;0.008&#x000a0;&#x000b1;&#x000a0;0.009 [&#x02212;0.026; 0.0093]</td><td rowspan="1" colspan="1">0.355</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Stroop<sub>congruent</sub> (s)</td><td rowspan="1" colspan="1">&#x02212;6.0&#x000a0;&#x000b1;&#x000a0;0.9</td><td rowspan="1" colspan="1">&#x02212;10.0&#x000a0;&#x000b1;&#x000a0;0.9</td><td rowspan="1" colspan="1">&#x02212;4.0&#x000a0;&#x000b1;&#x000a0;1.3 [&#x02212;6.5; &#x02212;1.5]</td><td rowspan="1" colspan="1">0.002</td><td rowspan="1" colspan="1">&#x02212;10.4&#x000a0;&#x000b1;&#x000a0;0.9</td><td rowspan="1" colspan="1">&#x02212;4.5&#x000a0;&#x000b1;&#x000a0;1.3 [&#x02212;6.9; &#x02212;2.0]</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Stroop<sub>incongruent</sub> (s)</td><td rowspan="1" colspan="1">&#x02212;10.9&#x000a0;&#x000b1;&#x000a0;1.5</td><td rowspan="1" colspan="1">&#x02212;17.7&#x000a0;&#x000b1;&#x000a0;1.5</td><td rowspan="1" colspan="1">&#x02212;6.8&#x000a0;&#x000b1;&#x000a0;2.0 [&#x02212;10.8; &#x02212;2.7]</td><td rowspan="1" colspan="1">0.001</td><td rowspan="1" colspan="1">&#x02212;17.5&#x000a0;&#x000b1;&#x000a0;1.4</td><td rowspan="1" colspan="1">&#x02212;6.5&#x000a0;&#x000b1;&#x000a0;2.0 [&#x02212;10.5; &#x02212;2.5]</td><td rowspan="1" colspan="1">0.001</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;PDQ<sub>total score</sub>*</td><td rowspan="1" colspan="1">&#x02212;7.8&#x000a0;&#x000b1;&#x000a0;0.9</td><td rowspan="1" colspan="1">&#x02212;12.2&#x000a0;&#x000b1;&#x000a0;0.9</td><td rowspan="1" colspan="1">&#x02212;4.4&#x000a0;&#x000b1;&#x000a0;1.2 [&#x02212;6.8; &#x02212;2.1]</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">&#x02212;13.5&#x000a0;&#x000b1;&#x000a0;0.9</td><td rowspan="1" colspan="1">&#x02212;5.7&#x000a0;&#x000b1;&#x000a0;1.2 [&#x02212;8.0; &#x02212;3.4]</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;PDQ<sub>attention/concentration</sub>*</td><td rowspan="1" colspan="1">&#x02212;2.2&#x000a0;&#x000b1;&#x000a0;0.3</td><td rowspan="1" colspan="1">&#x02212;3.7&#x000a0;&#x000b1;&#x000a0;0.3</td><td rowspan="1" colspan="1">&#x02212;1.5&#x000a0;&#x000b1;&#x000a0;0.4 [&#x02212;2.2; &#x02212;0.8]</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">&#x02212;4.1&#x000a0;&#x000b1;&#x000a0;0.3</td><td rowspan="1" colspan="1">&#x02212;1.9&#x000a0;&#x000b1;&#x000a0;0.4 [&#x02212;2.6; &#x02212;1.2]</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;PDQ<sub>prospective memory</sub>*</td><td rowspan="1" colspan="1">&#x02212;1.7&#x000a0;&#x000b1;&#x000a0;0.2</td><td rowspan="1" colspan="1">&#x02212;2.4&#x000a0;&#x000b1;&#x000a0;0.2</td><td rowspan="1" colspan="1">&#x02212;0.8&#x000a0;&#x000b1;&#x000a0;0.3 [&#x02212;1.3; &#x02212;0.2]</td><td rowspan="1" colspan="1">0.006</td><td rowspan="1" colspan="1">&#x02212;2.5&#x000a0;&#x000b1;&#x000a0;0.2</td><td rowspan="1" colspan="1">&#x02212;0.8&#x000a0;&#x000b1;&#x000a0;0.3 [&#x02212;1.4; &#x02212;0.3]</td><td rowspan="1" colspan="1">0.003</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;PDQ<sub>planning/organization</sub>*</td><td rowspan="1" colspan="1">&#x02212;2.3&#x000a0;&#x000b1;&#x000a0;0.3</td><td rowspan="1" colspan="1">&#x02212;3.3&#x000a0;&#x000b1;&#x000a0;0.3</td><td rowspan="1" colspan="1">&#x02212;1.0&#x000a0;&#x000b1;&#x000a0;0.4 [&#x02212;1.8; &#x02212;0.2]</td><td rowspan="1" colspan="1">0.012</td><td rowspan="1" colspan="1">&#x02212;3.9&#x000a0;&#x000b1;&#x000a0;0.3</td><td rowspan="1" colspan="1">&#x02212;1.6&#x000a0;&#x000b1;&#x000a0;0.4 [&#x02212;2.3; &#x02212;0.8]</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;PDQ<sub>retrospective memory</sub>*</td><td rowspan="1" colspan="1">&#x02212;1.7&#x000a0;&#x000b1;&#x000a0;0.3</td><td rowspan="1" colspan="1">&#x02212;2.6&#x000a0;&#x000b1;&#x000a0;0.3</td><td rowspan="1" colspan="1">&#x02212;1.0&#x000a0;&#x000b1;&#x000a0;0.3 [&#x02212;1.6; &#x02212;0.3]</td><td rowspan="1" colspan="1">0.004</td><td rowspan="1" colspan="1">&#x02212;3.0&#x000a0;&#x000b1;&#x000a0;0.2</td><td rowspan="1" colspan="1">&#x02212;1.3&#x000a0;&#x000b1;&#x000a0;0.3 [&#x02212;2.0; &#x02212;0.7]</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" colspan="8" rowspan="1">Secondary depression efficacy variables</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;MADRS total score</td><td rowspan="1" colspan="1">&#x02212;10.9&#x000a0;&#x000b1;&#x000a0;0.6</td><td rowspan="1" colspan="1">&#x02212;15.6&#x000a0;&#x000b1;&#x000a0;0.6</td><td rowspan="1" colspan="1">&#x02212;4.7&#x000a0;&#x000b1;&#x000a0;0.9 [&#x02212;6.4; &#x02212;3.0]</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">&#x02212;17.6&#x000a0;&#x000b1;&#x000a0;0.6</td><td rowspan="1" colspan="1">&#x02212;6.7&#x000a0;&#x000b1;&#x000a0;0.9 [&#x02212;8.4; &#x02212;5.0]</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;CGI-I score<xref ref-type="table-fn" rid="tfn2_2"><sup>b</sup></xref></td><td rowspan="1" colspan="1">2.85&#x000a0;&#x000b1;&#x000a0;0.08</td><td rowspan="1" colspan="1">2.24&#x000a0;&#x000b1;&#x000a0;0.08</td><td rowspan="1" colspan="1">&#x02212;0.61&#x000a0;&#x000b1;&#x000a0;0.11 [&#x02212;0.81; &#x02212;0.40]</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.99&#x000a0;&#x000b1;&#x000a0;0.07</td><td rowspan="1" colspan="1">&#x02212;0.86&#x000a0;&#x000b1;&#x000a0;0.11 [&#x02212;1.1; &#x02212;0.65]</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;CGI-S score</td><td rowspan="1" colspan="1">&#x02212;1.15&#x000a0;&#x000b1;&#x000a0;0.08</td><td rowspan="1" colspan="1">&#x02212;1.80&#x000a0;&#x000b1;&#x000a0;0.08</td><td rowspan="1" colspan="1">&#x02212;0.65&#x000a0;&#x000b1;&#x000a0;0.12 [&#x02212;0.88; &#x02212;0.42]</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">&#x02212;2.00&#x000a0;&#x000b1;&#x000a0;0.08</td><td rowspan="1" colspan="1">&#x02212;0.85&#x000a0;&#x000b1;&#x000a0;0.12 [&#x02212;1.1; &#x02212;0.62]</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;MADRS response (FAS, LOCF)<xref ref-type="table-fn" rid="tfn2_2"><sup>b</sup></xref></td><td rowspan="1" colspan="1">29.4%</td><td rowspan="1" colspan="1">47.7%</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">58.8%</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;MADRS remission (FAS, LOCF)<xref ref-type="table-fn" rid="tfn2_2"><sup>b</sup></xref></td><td rowspan="1" colspan="1">17.0%</td><td rowspan="1" colspan="1">29.5%</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">0.003</td><td rowspan="1" colspan="1">38.2%</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;CGI-I response (CGI-I &#x02a7d;2)<xref ref-type="table-fn" rid="tfn2_2"><sup>b</sup></xref></td><td rowspan="1" colspan="1">38.7%</td><td rowspan="1" colspan="1">61.7%</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">70.1%</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;CGI-S remission (CGI-S &#x02a7d;2)<xref ref-type="table-fn" rid="tfn2_2"><sup>b</sup></xref></td><td rowspan="1" colspan="1">19.6%</td><td rowspan="1" colspan="1">37.8%</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">42.6%</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="tfn2_1"><label>a</label><p>The negative mean composite z-score for placebo indicates that patients on placebo perform worse than average on cognition, i.e. it does not indicate that these patients deteriorated during treatment.</p></fn><fn id="tfn2_2"><label>b</label><p>Absolute value. *FAS, ANCOVA, LOCF. ANCOVA: analysis of covariance, CGI-I, Clinical Global Impression &#x02013; Improvement; CGI-S, Clinical Global Impression &#x02013; Severity; CI, confidence interval; CRT, choice reaction time task; DSST, Digit Symbol Substitution Test; FAS, full-analysis set; LOCF, last observation carried forward; MADRS, Montgomery-&#x000c5;sberg Depression Rating Scale; MMRM, mixed model for repeated measures; OC, observed cases; PDQ, Perceived Deficits Questionnaire; RAVLT, Rey Auditory Verbal Learning Test; SRT, simple reaction time task; TMT, trail making task.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec4-2"><title>Key secondary efficacy endpoints</title><p>Both doses of vortioxetine were significantly superior to placebo in the pre-defined key secondary efficacy analysis of the DSST score (<xref ref-type="table" rid="tab02">Table 2</xref>). For the RAVLT (acquisition), the <italic>p</italic>-value for each dose was &#x0003e;0.025, and the testing sequence stopped at this point. However, for the RAVLT (delayed recall), the <italic>p</italic>-value for each dose was &#x0003c;0.025.</p></sec><sec id="sec4-3"><title>Secondary efficacy endpoints</title><sec id="sec4-3-1"><title>Cognitive function</title><p>At week 8, separation from placebo (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05) was seen for all other measures of cognitive function (TMT-A/B; Stroop [congruent and incongruent]; SRT and CRT), with the exception of CRT for vortioxetine 20&#x000a0;mg (<xref ref-type="table" rid="tab02">Table 2</xref>). In <italic>post-hoc</italic> analyses, standardized effect sizes (Cohen's <italic>d</italic>) for the neuropsychological tests (FAS, OC) in which <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05 were 0.51 and 0.52 (DSST), 0.23 (RAVLT [acquisition] 10&#x000a0;mg), 0.31 and 0.28 (RAVLT [delayed recall]), 0.29 and 0.35 (TMT-B), 0.33 and 0.37 (Stroop congruent), 0.35 and 0.34 (Stroop incongruent), 0.29 and 0.29 (TMT-A), 0.41 and 0.26 (SRT), and 0.38 (CRT 10&#x000a0;mg) for vortioxetine 10 and 20&#x000a0;mg, respectively (<xref ref-type="fig" rid="fig01">Fig. 1</xref>). On the patient-rated PDQ total score and on PDQ subscale scores at week 8, patients in both vortioxetine groups separated from placebo (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05) (<xref ref-type="table" rid="tab02">Table 2</xref>).
<fig id="fig01" orientation="portrait" position="float"><label>Fig. 1.</label><caption><p>Standardized effect size (Cohen's <italic>d</italic>) for the neuropsychological tests (FAS, OC). DSST, Digit Symbol Substitution Test; FAS, full-analysis set; OC, observed cases; RAVLT, Rey Auditory Verbal Learning Test; TMT, Trail Making Test, Stroop; SRT, simple reaction time task; CRT, choice reaction time task. *<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05, **<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01, ***<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001 <italic>vs.</italic> placebo. p-values for TMT, Stroop, SRT and CRT are not corrected for multiplicity.</p></caption><graphic xlink:href="S1461145714000546_fig1"/></fig></p></sec><sec id="sec4-3-2"><title>Depressive symptoms</title><p>Patients in both vortioxetine groups separated from placebo in depressive symptom and CGI variables [MADRS total score, CGI-S score, CGI-I score, and response (&#x02a7e;50% reduction from baseline in MADRS total score or a CGI-I score &#x02a7d;2) and remission (MADRS total score &#x02a7d;10 or a CGI-S score &#x02a7d;2) rates] (<xref ref-type="table" rid="tab02">Table 2</xref>). Separation from placebo in the change from baseline in MADRS total score was seen from week 1 onward for vortioxetine 20&#x000a0;mg and from week 4 onward for vortioxetine 10&#x000a0;mg, with greater improvement at the higher dose (<xref ref-type="fig" rid="fig02">Fig. 2</xref>). Similar results were found using analysis of covariance (ANCOVA) [observed cases (OC) and last observation carried forward (LOCF)].
<fig id="fig02" orientation="portrait" position="float"><label>Fig. 2.</label><caption><p>Estimated Montgomery-&#x000c5;sberg Depression Rating Scale (MADRS) total scores from baseline to week 8 (FAS, MMRM by visit) and LOCF, FAS, ANCOVA). The mean improvement from baseline to week 8 in the MADRS total score was &#x02212;10.9 points (placebo), &#x02212;15.6 points (vortioxetine 10&#x000a0;mg), and &#x02212;17.6 points (vortioxetine 20&#x000a0;mg). ANCOVA, analysis of covariance; FAS, full-analysis set; LOCF, last observation carried forward; MMRM, mixed model for repeated measures. Patient numbers at each visit are shown below the <italic>x</italic>-axis for each treatment group. **<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01; ***<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001 <italic>vs.</italic> placebo. <italic>p</italic>-values are not corrected for multiplicity.</p></caption><graphic xlink:href="S1461145714000546_fig2"/></fig></p></sec><sec id="sec4-3-3"><title>Separation of effect on cognitive performance and depressive symptoms</title><p>After correction for the effect on MADRS, both vortioxetine doses improved cognitive performance, indicating an effect on cognitive function independent of its effect on improving depressive symptoms. At week 8, with the MADRS total score as the depression mediator, the pre-specified multiple regression analyses (path analysis) based on the FAS (ANCOVA, LOCF) showed a significant direct effect on the composite z-score (primary endpoint) and on the mean difference to placebo in DSST score (key secondary endpoint), which was the main driver in the primary analysis (<xref ref-type="table" rid="tab03">Table 3</xref>).
<table-wrap id="tab03" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Change from baseline to week 8 in composite z-score and DSST (number of correct symbols) &#x02013; depression mediator: change from baseline in Montgomery-&#x000c5;sberg Depression Rating Scale (MADRS) total score</p></caption><alternatives><graphic xlink:href="S1461145714000546_tab3"/><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><thead><tr><th rowspan="2" valign="bottom" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">Vortioxetine 10&#x000a0;mg</th><th align="left" rowspan="1" colspan="1">Vortioxetine 20&#x000a0;mg</th></tr><tr><th colspan="2" align="left" rowspan="1">Difference to placebo at week 8 (FAS, LOCF)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">All patients</td><td rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;193</td><td rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;204</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Effect on composite z-score after correcting for effect on MADRS</td><td rowspan="1" colspan="1">0.23***</td><td rowspan="1" colspan="1">0.15<xref ref-type="table-fn" rid="tfn3_1">*</xref></td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Effect on DSST after correction for effect on MADRS</td><td rowspan="1" colspan="1">2.59**</td><td rowspan="1" colspan="1">2.23**</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Direct treatment effect: % (95% CI) (FAS, LOCF)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x000a0;Composite z-score</td><td rowspan="1" colspan="1">64 (47; 82)</td><td rowspan="1" colspan="1">48 (23; 73)</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;DSST<sub>correct symbols</sub></td><td rowspan="1" colspan="1">66 (47; 84)</td><td rowspan="1" colspan="1">56 (34; 78)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Difference to placebo at week 8 (FAS, MMRM)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Non-responders<xref ref-type="table-fn" rid="tfn3_2"><sup>&#x000a7;</sup></xref></td><td rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;92</td><td rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;68</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Composite z-score</td><td rowspan="1" colspan="1">0.20<xref ref-type="table-fn" rid="tfn3_1">*</xref></td><td rowspan="1" colspan="1">0.28**</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;DSST<sub>correct symbols</sub></td><td rowspan="1" colspan="1">2.25<xref ref-type="table-fn" rid="tfn3_1">*</xref></td><td rowspan="1" colspan="1">2.88**</td></tr><tr><td rowspan="1" colspan="1">Non-remitters (MADRS&#x000a0;&#x0003e;&#x000a0;10)</td><td rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;123</td><td rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;110</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;Composite z-score</td><td rowspan="1" colspan="1">0.26**</td><td rowspan="1" colspan="1">0.28**</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;DSST<sub>correct symbols</sub></td><td rowspan="1" colspan="1">3.05**</td><td rowspan="1" colspan="1">3.53***</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="tfn3_1"><label>*</label><p><italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05, **<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01, ***<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001 <italic>vs.</italic> placebo.</p></fn><fn id="tfn3_2"><label>&#x000a7;</label><p>&#x0003c;50% reduction from baseline to week 8 in MADRS total score.</p></fn></table-wrap-foot></table-wrap></p><p>The results of multiple regression analyses (path analysis) indicate that one-half to two-thirds of the treatment effect was a direct effect on cognitive performance (composite z-score and DSST) at week 8 (<xref ref-type="table" rid="tab03">Table 3</xref>).</p><p>In addition, the dissociation between improvement in cognitive function and improvement of depressive symptoms was further supported by <italic>post-hoc</italic> analyses indicating that both vortioxetine doses improved cognitive performance (composite z-score and DSST) at week 8 in the subgroup of patients who were non-responders and the subgroup of patients who were non-remitters (<xref ref-type="table" rid="tab03">Table 3</xref>).</p><p>The direct effects on the primary endpoint were in general supported by the direct effects estimated for the secondary neuropsychological tests. For Stroop incongruent and congruent, the direct effects were 70 and 84%, respectively, for vortioxetine 10&#x000a0;mg <italic>vs.</italic> placebo, and 58 and 80%, respectively, for vortioxetine 20&#x000a0;mg <italic>vs.</italic> placebo. For TMT-A and B the direct effects were 60 and 71%, respectively, for vortioxetine 10&#x000a0;mg <italic>vs.</italic> placebo, and 51 and 67%, respectively, for vortioxetine 20&#x000a0;mg <italic>vs.</italic> placebo. For SRT and CRT, the direct effects were 66 and 67%, respectively, for vortioxetine 10&#x000a0;mg <italic>vs.</italic> placebo. For SRT the direct effect was 26% for vortioxetine 20&#x000a0;mg <italic>vs.</italic> placebo. For CRT, vortioxetine 20&#x000a0;mg <italic>vs.</italic> placebo, the estimation of the direct effect was not possible, as the treatment effects with and without correcting for the change from baseline to week 8 in the MADRS total score had different signs.</p></sec></sec></sec><sec id="sec5"><title>Safety and tolerability</title><sec id="sec5-1"><title>Treatment-emergent adverse events (TEAEs)</title><p>During the 8&#x000a0;wk treatment period, the proportions of patients with TEAEs were 38.3% (placebo: <italic>n</italic>&#x000a0;=&#x000a0;75), 46.2% (vortioxetine 10&#x000a0;mg; <italic>n</italic>&#x000a0;=&#x000a0;90) and 52.7% (vortioxetine 20&#x000a0;mg; <italic>n</italic>&#x000a0;=&#x000a0;109). Common AEs (incidence &#x02a7e;5% for vortioxetine) were nausea (4.1, 16.4, 20.8%) and headache (7.1, 8.2, 12.6%) for placebo, vortioxetine 10&#x000a0;mg and vortioxetine 20&#x000a0;mg, respectively. During treatment, 22 patients withdrew because of TEAEs (see Supplementary Material, Fig. S1). TEAEs leading to withdrawal of &#x02a7e;2 patients were nausea (1.9%) and headache (1.0%), (vortioxetine 20&#x000a0;mg), and disturbance in attention (1.0%) and depression (1.0%) (placebo).</p><p>No TEAEs related to suicide or self-harm were found. The C-SSRS data showed no clinically relevant differences between groups at screening or during the study. None of the patients had suicidal behavior during treatment and the proportions of patients with suicidal ideation were 11% (placebo), 9.3% (vortioxetine 10&#x000a0;mg) and 13% (vortioxetine 20&#x000a0;mg). Improved scores from baseline to week 8 for MADRS item 10 (suicidal thoughts) were seen in all treatment groups.</p><p>Serious AEs were reported by 4 patients, 2 patients in the placebo group (cholecystitis and hiatus hernia) and 2 patients in the vortioxetine 20&#x000a0;mg group (hypertension and type I diabetes). No deaths occurred during this study. Clinically relevant changes over time or differences between treatment groups were not observed in clinical laboratory test results, vital signs, weight, or ECG parameters.</p></sec></sec><sec sec-type="discussion" id="sec6"><title>Discussion</title><p>Although antidepressants are suggested to improve cognitive function to some degree in patients with MDD, there is a lack of adequate and well-controlled studies to investigate this (Biringer et al., <xref rid="ref4" ref-type="bibr">2009</xref>; McIntyre et al., <xref rid="ref24" ref-type="bibr">2013</xref>). This is the first large placebo-controlled randomized study to report a statistically significant improvement in objectively measured cognitive performance in adult patients (aged &#x02a7d;65&#x000a0;yr) with recurrent MDD, wherein the primary outcome measure evaluated multi-domains of cognitive function. In addition to demonstrating efficacy on a composite cognition score based on two tests covering several domains of relevance for patients with MDD, improvement with vortioxetine treatment was also noted on secondary objective and subjective measures of cognitive function. Improvement <italic>vs.</italic> placebo was seen on all included measures of executive function, attention, and processing speed, as well as with learning and memory.</p><p>The clinical relevance of the significant effect of vortioxetine on objective neuropsychological test scores was supported by the magnitude of the standardized effect sizes, which ranged from 0.23 to 0.52 [Cohen's <italic>d</italic>, <xref ref-type="fig" rid="fig01">Fig. 1</xref>)] where <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05 and were above the clinically meaningful threshold of 0.2 (Cohen, <xref rid="ref9" ref-type="bibr">1988</xref>). The present study extended the evidence of the positive effect of vortioxetine on cognitive function previously demonstrated in patients aged &#x02a7e;65 yr with MDD (Katona et al., <xref rid="ref20" ref-type="bibr">2012</xref>), in which vortioxetine separated from placebo in both the DSST and the RAVLT with standardized effect sizes [(0.25 for the DSST, 0.27 for the RAVLT (acquisition) and 0.24 for the RAVLT (delayed recall)] a little lower than those found in the present study. The magnitude of the observed effect on cognitive dysfunction should be contextualized in studies in patients with MDD. The standardized effect size of the deficits seen in MDD patients is typically 0.2&#x02013;0.6 below what would be normal, depending on the cognitive domain (Rund et al., <xref rid="ref36" ref-type="bibr">2006</xref>; Lee et al., <xref rid="ref23" ref-type="bibr">2012</xref>; Rock et al., <xref rid="ref34" ref-type="bibr">2013</xref>). For comparison, cognitive dysfunction in disorders such as Alzheimer's disease is greater than in MDD by several <sc>s.d.</sc>, and the treatment effect with the commonly used cholinesterase inhibitors show standardized effect sizes of approximately 0.3 (Rockwood, <xref rid="ref35" ref-type="bibr">2004</xref>), although caution must be exercised when comparing different studies.</p><p>There is little evidence that current antidepressants improve cognitive function in patients with MDD independently of their effect on depressive symptoms. In the present study the efficacy of both doses of vortioxetine on cognitive function was largely a direct and independent effect, rather than an epiphenomenon of broad-based symptom improvement in depression. The direct effect is suggested by the results of the path and subgroup analyses. Path analysis, previously referred to as causal modeling, is an extension of a multiple linear regression with its own unique assumptions and conventions (Streiner, <xref rid="ref38" ref-type="bibr">2005</xref>). A positive effect on cognitive performance was observed for both doses of vortioxetine after correction for the alleviation of depressive symptoms. The proportions of direct effect were 64 and 48% for vortioxetine 10 and 20&#x000a0;mg, respectively for the composite z-score and 66 and 56%, respectively for the DSST score. This supports the previous findings revealing more than two-thirds of the effect on cognitive function is a direct effect (Katona et al., <xref rid="ref20" ref-type="bibr">2012</xref>). In addition, vortioxetine's direct effect is also suggested by improved cognitive function in the subset of patients who were either non-responders or non-remitters.</p><p>Subjectively experienced cognitive function and objective neuropsychological assessments in patients with affective disorders are not associated to a great extent (e.g. Svendsen et al., <xref rid="ref39" ref-type="bibr">2012</xref>; Naismith et al., <xref rid="ref28" ref-type="bibr">2007</xref>). In this study, in addition to demonstrating efficacy on disparate objective measures of cognitive function, vortioxetine treatment improved subjective measures of cognitive function, as assessed by the PDQ in the domains of prospective/retrospective memory, attention/concentration, and planning and organization. The result from this patient-rated assessment tool provides additional support for the clinical relevance of the observed treatment differences in the depressed population, as robust treatment differences were found both in objective and subjective tests.</p><p>Several expert guidelines posit that achieving remission from depressive symptoms should be the primary therapeutic objective in depression (Zimmerman et al., <xref rid="ref43" ref-type="bibr">2008</xref>). The definition of the remitted state is subject of debate, and often a cut-off on a symptom severity scale has been applied as a surrogate measure. Nonetheless, patients who meet such symptom-based definitions of remission often do not consider themselves in a remitted state, and a large proportion of these individuals report symptoms such as impaired concentration (Zimmerman et al., <xref rid="ref44" ref-type="bibr">2012</xref>). Since improvement in cognition significantly influences functional recovery from an MDE, it is important to objectively measure cognitive function in clinical studies. Moreover, surveys of outpatients with MDD indicate that the presence of positive mental health, return to one's normal self, and return to a premorbid level of functioning are the principal desired goals of treatment (Zimmerman et al., <xref rid="ref44" ref-type="bibr">2012</xref>), suggesting a role and a need for assessment tools complementary to the conventional symptom-based clinician-administered scales. In the present study, capturing the patient's perspective on their cognitive function as well as using objective neuropsychological tests showed improvement in cognitive function that was not captured by the MADRS, suggesting that these measures capture unique aspects of depression not otherwise addressed.</p><p>The 5-HT system not only plays a critical role in the regulation of mood, but is also intimately involved in the regulation of cognitive function, as evidenced by pre-clinical and clinical studies (e.g. Booij et al., <xref rid="ref5" ref-type="bibr">2005</xref>; Jensen et al., <xref rid="ref19" ref-type="bibr">2013</xref>). For example, available evidence indicates that several 5-HT receptor subtypes (e.g. 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, 5-HT<sub>2</sub>, 5-HT<sub>3</sub>, 5-HT<sub>4</sub>, 5-HT<sub>6</sub> and 5-HT<sub>7</sub> receptors), including the receptor targets of vortioxetine, have the potential to modulate neurotransmitter systems that are essential for regulation of cognitive function (e.g. glutamate, acetylcholine, histamine, dopamine and noradrenaline [M&#x000f8;rk et al., <xref rid="ref26" ref-type="bibr">2013</xref>; Pehrson and Sanchez, <xref rid="ref29" ref-type="bibr">2013</xref>; Pehrson et al., <xref rid="ref30" ref-type="bibr">2013a</xref>]). In line with this, electroencephalographic studies in rats have indicated that vortioxetine activates cortical networks that are associated with cognitive processes and that 5-HT<sub>1A</sub> receptor agonism and 5-HT<sub>3</sub> and 5-HT<sub>7</sub> receptor antagonism contribute to these activating effects of vortioxetine (Sanchez et al., <xref rid="ref37" ref-type="bibr">2012</xref>). Furthermore, <italic>in vivo</italic> and <italic>in vitro</italic> electrophysiology studies of vortioxetine have indicated that disinhibition of GABA interneurons plays an important role in the activation of the cortical and hippocampal networks involved in cognitive processes and that 5-HT<sub>3</sub> receptor antagonism appears to play a key role (Dale et al., <xref rid="ref10" ref-type="bibr">2013</xref>; du Jardin et al., <xref rid="ref11" ref-type="bibr">2013</xref>; M&#x000f8;rk et al., <xref rid="ref26" ref-type="bibr">2013</xref>; Pehrson et al., <xref rid="ref30" ref-type="bibr">2013a</xref>, <xref rid="ref31" ref-type="bibr">b</xref>). Finally, preclinical studies in animal models assessing the effect of vortioxetine on attention, learning and memory, and executive function (cognitive flexibility) indicate that vortioxetine has a profile distinct from those of other antidepressants (escitalopram and duloxetine) and the potential to improve cognitive function at doses associated with clinically relevant exposures (Sanchez et al., <xref rid="ref25" ref-type="bibr">2012</xref>; du Jardin et al., <xref rid="ref11" ref-type="bibr">2013</xref>; M&#x000f8;rk et al., <xref rid="ref26" ref-type="bibr">2013</xref>; Pehrson et al., <xref rid="ref31" ref-type="bibr">2013b</xref>).</p><p>In addition to demonstrating efficacy on cognitive function, both doses of vortioxetine had clinically meaningful effects on baseline-to-endpoint change in depressive symptom reduction, MADRS response and remission rates, as well as CGI measures. A dose-response in the present study showing a greater improvement of the higher dose of vortioxetine on the MADRS total score was not reflected on the cognitive performance scores, indicating that vortioxetine exerts its antidepressant and beneficial effect on cognitive function via a distinct mechanism. There is evidence that cognitive function varies independently of mood state in MDD. In particular, improvements in cognitive performance do not necessarily track improvement in mood symptoms, which may reflect the distinct neuronal basis of cognitive control and emotion regulation as it relates to depression (Harmer et al., <xref rid="ref15" ref-type="bibr">2002</xref>; Campbell and Macqueen, <xref rid="ref8" ref-type="bibr">2004</xref>; Murrough et al., <xref rid="ref27" ref-type="bibr">2011</xref>). The present study supports this, as an effect on cognitive function was shown to be independent of the effect on mood symptoms. It also raises the point that the effect on cognition and the patient's potential return to normal functioning may occur despite an inadequate response to mood symptoms, and this warrants further investigation.</p><p>The most commonly reported AEs (incidence &#x02a7e;5% for vortioxetine) were nausea and headache. The discontinuation rate due to AEs was similar to the rate for placebo, suggesting favorable tolerability profile. No safety concerns emerged for either dose of vortioxetine during this study.</p><p>Limitations of the present study include, but are not limited to; duration of treatment for only 8&#x000a0;wk; eligible patients may not be representative of adults with MDD who are seen in normal clinical practice; exclusion of individuals presenting with an index episode and/or milder baseline severity and our results only pertain to the two doses evaluated.</p><p>Notwithstanding, this appears to be the first large randomized study in adults (aged &#x02a7d;65&#x000a0;yr) to document a beneficial effect on a composite measure of cognitive function in MDD, wherein the pre-defined primary clinical outcome was cognitive performance as well as consistent improvement across a range of neuropsychological tests. The clinical relevance of the results herein is suggested by the magnitude of the standardized effect sizes and the improvements in patient-reported cognitive function. Future vistas could endeavor to determine the principal molecular/circuit targets of vortioxetine in adults with MDD, and possible additive or synergistic effects when combined with behavioral strategies (e.g. cognitive remediation) as well as assessing the effect of vortioxetine on cognitive function in the absence of depressive symptoms (e.g. residual cognitive symptoms in remitted patients).</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data"><label>Supplementary Material</label><caption><p>Supplementary information supplied by authors.</p></caption><media xlink:href="S1461145714000546sup001.pptx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data"><label>Supplementary Material</label><caption><p>Supplementary information supplied by authors.</p></caption><media xlink:href="S1461145714000546sup002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="ack"><title>Acknowledgments</title><p>The authors would like to thank all patients for their participation in the study. The authors gratefully acknowledge the participation of the patients and the following investigators in the psychiatric sites in the trial: <italic>Australia</italic>: Michael Theodoros, Isaac Schweitzer, Chee Ng, Dennis Liu, <italic>Canada</italic>: Linda Beauclair, Nabil Phillips, Pratap Chokka, Diane McIntosh, Satpal Girgla, Ranjith Chandrasena, <italic>Finland</italic>: Ulla Lepola, Anna Savela, Riitta Riihikangas, Antti Ahokas, Marja Piril&#x000e4;, Marko Sorvaniemi, Hannu Koponen, Martti Heikkinen, Markku Timonen, <italic>France</italic>: Francis Gheysen, Philippe Desbonnet, Daniel Bonnaffoux, Bernard Bonin, <italic>Germany</italic>: Klaus-Ulrich Oehler, Hermann-Josef Gertz, Bettina Bergtholdt, Frank Godemann, Andreas Mahler, Johannes Boehringer, Klaus-Christian Steinwachs, Klaus Sallach, Jana Thomsen, <italic>Latvia</italic>:, Andris Arajs, Aleksandrs Verzbickis, Biruta Kupca, Linda Keruze, Ilona Paegle, <italic>Mexico</italic>: Juan Vazquez Hernandez, Miguel Herrera, Gabriel Bernal, Jos&#x000e9; Alfonso Ontiveros, Omar Kawas, Serbia:, Dusica Lecic Tosevski, Grozdanko Grbesa, Dragana Ignjatovic Ristic, Aleksandar Miljatovic, <italic>Slovakia</italic>: Peter Molcan, Abdul Shinwari, Rastislav Korba, Maria Hastova, Juraj Mrazik, Nada Kuriackova, <italic>South Africa</italic>: Juan Schronen, Pravitha Miseer, Ian Taylor, <italic>Ukraine</italic>: Viktoriya Verbenko, Nataliya Maruta, Gennadiy Zilberblat, Andrii Skrypnikov, Pavlo Palamarchuk, Volodymyr Abramov, Vitalii Pishel, Sofiya Rymsha, Bogdan Kulyk, Oleg Chaban, Iryna Spirina, Svitlana Kazakova, Valerii Pidkorytov, <italic>United States</italic>: Mohammed Bari, Carlos Danger, Armen Goenjian, Richard Knapp, Paul Miller, William Patterson, Charmaine Semeniuk, Paul Miller, Ram Shrivastava, Alan Yeo, Michael Liebowitz and Nick Vatakis. The authors thank D. J. Simpson (H. Lundbeck A/S) for providing support in the preparation, revision, and editing of the manuscript. The authors are entirely responsible for the scientific content of this paper.</p></ack><sec id="sec7"><title>Statement of Interest</title><p><bold>Sponsor:</bold> H. Lundbeck A/S sponsored this study as part of a joint clinical development program with the Takeda Pharmaceutical Company, Ltd. <uri xlink:type="simple" xlink:href="http://www.ClinicalTrials.gov">www.ClinicalTrials.gov</uri>: Efficacy study of vortioxetine on cognitive dysfunction in adult patients with major depressive disorder (FOCUS); NCT01422213, <uri xlink:type="simple" xlink:href="http://clinicaltrials.gov/ct2/show/NCT01422213?term=NCT01422213&#x00026;rank=1">http://clinicaltrials.gov/ct2/show/NCT01422213?term=NCT01422213&#x00026;rank=1</uri>. Lundbeck was involved in the study design, in the collection, analysis and interpretation of data, in the writing of the report, and in the decision to submit the paper for publication. In the last 36 months Dr RS McIntyre has received research grant support from Lundbeck, Astra Zeneca, Pfizer, Shire, Otsuka, Bristol Myers Squibb, National Institute of Mental Health, Stanley Medical Research Institute, Canadian Institutes for Health Research, and The Brain and Behavior Research Foundation. Dr RS McIntyre has also received speaker/consultant fees from Lundbeck, Pfizer, Astra Zeneca, Elli Lilly, Janssen Ortho, Sunovion, Takeda, Forest, Otsuka, Bristol Myers Squibb and Shire. Drs Lophaven and Olsen are employees of H. Lundbeck A/S, the manufacturer of vortioxetine.</p></sec><sec id="sec8"><title>Supplementary material</title><p>For supplementary material accompanying this paper, visit <uri xlink:type="simple" xlink:href="http://dx.doi.org/10.1017/S1461145714000546">http://dx.doi.org/10.1017/S1461145714000546</uri>.</p></sec><ref-list id="reflist1"><title>References</title><ref id="ref1"><mixed-citation publication-type="journal"><name><surname>Alvarez</surname><given-names>E</given-names></name>, <name><surname>Perez</surname><given-names>V</given-names></name>, <name><surname>Dragheim</surname><given-names>M</given-names></name>, <name><surname>Loft</surname><given-names>H</given-names></name>, <name><surname>Artigas</surname><given-names>F</given-names></name> (<year>2012</year>) <article-title>A double-blind, randomized, placebo-controlled, active-reference study of Lu AA21004 in patients with major depressive disorder (MDD)</article-title>. <source>Int J Neuropsychopharmacol</source><volume>15</volume>:<fpage>589</fpage>&#x02013;<lpage>600</lpage><pub-id pub-id-type="pmid">21767441</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal"><name><surname>Bang-Andersen</surname><given-names>B</given-names></name>, <name><surname>Ruhland</surname><given-names>T</given-names></name>, <name><surname>J&#x000f8;rgensen</surname><given-names>M</given-names></name>, <name><surname>Smith</surname><given-names>G</given-names></name>, <name><surname>Frederiksen</surname><given-names>K</given-names></name>, <name><surname>Jensen</surname><given-names>KG</given-names></name>, <name><surname>Zhong</surname><given-names>H</given-names></name>, <name><surname>Nielsen</surname><given-names>SM</given-names></name>, <name><surname>Hogg</surname><given-names>S</given-names></name>, <name><surname>M&#x000f8;rk</surname><given-names>A</given-names></name>, <name><surname>Stensb&#x000f8;l</surname><given-names>TB</given-names></name> (<year>2011</year>) <article-title>Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder</article-title>. <source>J Med Chem</source><volume>54</volume>:<fpage>3206</fpage>&#x02013;<lpage>3221</lpage><pub-id pub-id-type="pmid">21486038</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal"><name><surname>Baune</surname><given-names>BT</given-names></name>, <name><surname>Miller</surname><given-names>R</given-names></name>, <name><surname>McAfoose</surname><given-names>J</given-names></name>, <name><surname>Johnson</surname><given-names>M</given-names></name>, <name><surname>Quirk</surname><given-names>F</given-names></name>, <name><surname>Mitchel</surname><given-names>D</given-names></name> (<year>2010</year>) <article-title>The role of cognitive impairment in general functioning in major depression</article-title>. <source>Psychiatry Res</source><volume>76</volume>:<fpage>183</fpage>&#x02013;<lpage>189</lpage><pub-id pub-id-type="pmid">20138370</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal"><name><surname>Biringer</surname><given-names>E</given-names></name>, <name><surname>Rongve</surname><given-names>A</given-names></name>, <name><surname>Lund</surname><given-names>A</given-names></name> (<year>2009</year>) <article-title>A review of modern antidepressants&#x02019; effects on neurocognitive function</article-title>. <source>Curr Psych Rev</source><volume>5</volume>:<fpage>164</fpage>&#x02013;<lpage>174</lpage></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal"><name><surname>Booij</surname><given-names>L</given-names></name>, <name><surname>Van der Does</surname><given-names>AJ</given-names></name>, <name><surname>Haffmans</surname><given-names>PM</given-names></name>, <name><surname>Reidel</surname><given-names>WJ</given-names></name>, <name><surname>Fekkes</surname><given-names>D</given-names></name>, <name><surname>Blom</surname><given-names>MJ</given-names></name> (<year>2005</year>) <article-title>The effects of high-dose and low-dose tryptophan depletion on mood and cognitive functions of remitted depressed patients</article-title>. <source>J Psychopharmacology</source><volume>19</volume>:<fpage>267</fpage>&#x02013;<lpage>275</lpage></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal"><name><surname>Boulenger</surname><given-names>JP</given-names></name>, <name><surname>Loft</surname><given-names>H</given-names></name>, <name><surname>Olsen</surname><given-names>CK</given-names></name> (<year>2014</year>) <article-title>Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20&#x000a0;mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder</article-title>. <source>Int Clin Psychopharmacol</source><volume>29</volume>:<fpage>138</fpage>&#x02013;<lpage>149</lpage><pub-id pub-id-type="pmid">24257717</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal"><name><surname>Buist-Bouwman</surname><given-names>MA</given-names></name>, <name><surname>Ormel</surname><given-names>J</given-names></name>, <name><surname>de Graaf</surname><given-names>R</given-names></name>, <name><surname>de Jonge</surname><given-names>P</given-names></name>, <name><surname>van Sonderen</surname><given-names>E</given-names></name>, <name><surname>Alonso</surname><given-names>J</given-names></name>, <name><surname>Bruffaerts</surname><given-names>R</given-names></name>, <name><surname>Vollebergh</surname><given-names>WA</given-names></name>; <collab>ESEMeD/MHEDEA 2000 investigators</collab> (<year>2008</year>) <article-title>Mediators of the association between depression and role functioning</article-title>. <source>Acta Psychiatr Scand</source><volume>118</volume>:<fpage>451</fpage>&#x02013;<lpage>458</lpage><pub-id pub-id-type="pmid">18853945</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal"><name><surname>Campbell</surname><given-names>S</given-names></name>, <name><surname>Macqueen</surname><given-names>G</given-names></name> (<year>2004</year>) <article-title>The role of the hippocampus in the pathophysiology of major depression</article-title>. <source>J Psychiatry Neurosci</source><volume>29</volume>:<fpage>417</fpage>&#x02013;<lpage>426</lpage><pub-id pub-id-type="pmid">15644983</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="book"><name><surname>Cohen</surname><given-names>J</given-names></name> (<year>1988</year>) <source>Statistical power analysis for the behavioral sciences</source>, <edition>Second Edition</edition>
<publisher-loc>Hillsdale, NJ</publisher-loc>: <publisher-name>Lawrence Erlbaum Associates, Publishers</publisher-name></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal"><name><surname>Dale</surname><given-names>E</given-names></name>, <name><surname>Zhang</surname><given-names>H</given-names></name>, <name><surname>Plath</surname><given-names>N</given-names></name>, <name><surname>Sanchez</surname><given-names>C</given-names></name> (<year>2013</year>) <article-title>Vortioxetine's (Lu AA21004) memory enhancing properties in preclinical rat models may involve an increase of pyramidal cell output &#x02013; rat hippocampal slice study</article-title>. <source>Biol Psychiatry</source><volume>73</volume> (<issue>Suppl. 9</issue>):<fpage>213S</fpage></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal"><name><surname>du Jardin</surname><given-names>KG</given-names></name>, <name><surname>Jensen</surname><given-names>JB</given-names></name>, <name><surname>Sanchez</surname><given-names>C</given-names></name>, <name><surname>Pehrson</surname><given-names>AL</given-names></name> (<year>2014</year>) <article-title>Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism</article-title>. <source>Eur Neuropsychopharmacol</source><volume>24</volume>:<fpage>160</fpage>&#x02013;<lpage>171</lpage><pub-id pub-id-type="pmid">23916504</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal"><name><surname>Greenberg</surname><given-names>PE</given-names></name>, <name><surname>Kessler</surname><given-names>RC</given-names></name>, <name><surname>Birnbaum</surname><given-names>HG</given-names></name>, <name><surname>Leong</surname><given-names>SA</given-names></name>, <name><surname>Lowe</surname><given-names>SW</given-names></name>, <name><surname>Berglund</surname><given-names>PA</given-names></name>, <name><surname>Corey-Lisle</surname><given-names>PK</given-names></name> (<year>2003</year>) <article-title>The economic burden of depression in the United States: how did it change between 1990 and 2000?</article-title><source>J Clin Psychiatry</source><volume>64</volume>:<fpage>1465</fpage>&#x02013;<lpage>1475</lpage><pub-id pub-id-type="pmid">14728109</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal"><name><surname>Greer</surname><given-names>TL</given-names></name>, <name><surname>Kurian</surname><given-names>BT</given-names></name>, <name><surname>Trivedi</surname><given-names>MH</given-names></name> (<year>2010</year>) <article-title>Defining and measuring functional recovery from depression</article-title>. <source>CNS Drugs</source><volume>24</volume>:<fpage>267</fpage>&#x02013;<lpage>284</lpage><pub-id pub-id-type="pmid">20297853</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal"><name><surname>Hammar</surname><given-names>A</given-names></name>, <name><surname>Ardal</surname><given-names>G</given-names></name> (<year>2009</year>) <article-title>Cognitive functioning in major depression &#x02013; a summary</article-title>. <source>Front Hum Neurosci</source><volume>3</volume>:<fpage>26</fpage>. doi: <pub-id pub-id-type="doi">10.3389/neuro.09.026.2009</pub-id><pub-id pub-id-type="pmid">19826496</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal"><name><surname>Harmer</surname><given-names>CJ</given-names></name>, <name><surname>Bhagwagar</surname><given-names>Z</given-names></name>, <name><surname>Cowen</surname><given-names>PJ</given-names></name>, <name><surname>Goodwin</surname><given-names>GM</given-names></name> (<year>2002</year>) <article-title>Acute administration of citalopram facilitates memory consolidation in healthy volunteers</article-title>. <source>Psychopharmacology (Berl)</source><volume>163</volume>:<fpage>106</fpage>&#x02013;<lpage>110</lpage><pub-id pub-id-type="pmid">12185407</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal"><name><surname>Henigsberg</surname><given-names>N</given-names></name>, <name><surname>Mahableshwarkar</surname><given-names>A</given-names></name>, <name><surname>Jacobsen</surname><given-names>P</given-names></name>, <name><surname>Chen</surname><given-names>Y</given-names></name>, <name><surname>Thase</surname><given-names>ME</given-names></name> (<year>2012</year>) <article-title>A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder</article-title>. <source>J Clin Psychiatry</source><volume>73</volume>:<fpage>953</fpage>&#x02013;<lpage>959</lpage><pub-id pub-id-type="pmid">22901346</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="other"><collab>ICH Harmonised Tripartite Guideline E6: Guideline for Good Clinical Practice</collab> (<year>1996</year>) <uri xlink:type="simple" xlink:href="http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073122.pdf">http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073122.pdf</uri></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal"><name><surname>Jaeger</surname><given-names>J</given-names></name>, <name><surname>Berns</surname><given-names>S</given-names></name>, <name><surname>Uzelac</surname><given-names>S</given-names></name>, <name><surname>Davis-Conway</surname><given-names>S</given-names></name> (<year>2006</year>) <article-title>Neurocognitive deficits and disability in major depressive disorder</article-title>. <source>Psychiatry Res</source><volume>145</volume>:<fpage>39</fpage>&#x02013;<lpage>48</lpage><pub-id pub-id-type="pmid">17045658</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal"><name><surname>Jensen</surname><given-names>JB</given-names></name>, <name><surname>du Jardin</surname><given-names>KG</given-names></name>, <name><surname>Song</surname><given-names>D</given-names></name>, <name><surname>Budac</surname><given-names>D</given-names></name>, <name><surname>Smagin</surname><given-names>G</given-names></name>, <name><surname>Sanchez</surname><given-names>C</given-names></name>, <name><surname>Perhson</surname><given-names>AL</given-names></name> (<year>2013</year>) <article-title>Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: evidence for direct serotonin receptor modulation</article-title>. <source>Acta Neuropsychiatrica</source><volume>25</volume> (<issue>Suppl. 1</issue>):<fpage>20</fpage></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal"><name><surname>Katona</surname><given-names>C</given-names></name>, <name><surname>Hansen</surname><given-names>T</given-names></name>, <name><surname>Olsen</surname><given-names>CK</given-names></name> (<year>2012</year>) <article-title>A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder</article-title>. <source>Int Clin Psychopharmacol</source><volume>27</volume>:<fpage>215</fpage>&#x02013;<lpage>223</lpage><pub-id pub-id-type="pmid">22572889</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="other"><name><surname>Laughren</surname><given-names>T</given-names></name> (<year>2006</year>) Food and Drug Administration, Center for Drug Evaluation and Research. Memorandum on Suicidality. 16-Nov-2006. <uri xlink:type="simple" xlink:href="http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-fda.pdf">http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-fda.pdf</uri></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal"><name><surname>Lecrubier</surname><given-names>Y</given-names></name>, <name><surname>Sheehan</surname><given-names>DV</given-names></name>, <name><surname>Weiller</surname><given-names>E</given-names></name>, <name><surname>Amorim</surname><given-names>P</given-names></name>, <name><surname>Bonora</surname><given-names>I</given-names></name>, <name><surname>Sheehan</surname><given-names>KH</given-names></name>, <name><surname>Janavs</surname><given-names>J</given-names></name>, <name><surname>Dunbar</surname><given-names>GC</given-names></name> (<year>1997</year>) <article-title>The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI</article-title>. <source>Eur Psychiatry</source><volume>12</volume>:<fpage>224</fpage>&#x02013;<lpage>231</lpage></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>RS</given-names></name>, <name><surname>Hermens</surname><given-names>DF</given-names></name>, <name><surname>Porter</surname><given-names>MA</given-names></name>, <name><surname>Redoblado-Hodge</surname><given-names>MA</given-names></name> (<year>2012</year>) <article-title>A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder</article-title>. <source>J Affect Disord</source><volume>140</volume>:<fpage>113</fpage>&#x02013;<lpage>124</lpage><pub-id pub-id-type="pmid">22088608</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal"><name><surname>McIntyre</surname><given-names>RS</given-names></name>, <name><surname>Cha</surname><given-names>DS</given-names></name>, <name><surname>Soczynska</surname><given-names>JK</given-names></name>, <name><surname>Woldeyohannes</surname><given-names>HO</given-names></name>, <name><surname>Gallaugher</surname><given-names>LA</given-names></name>, <name><surname>Kudlow</surname><given-names>P</given-names></name>, <name><surname>Alsuwaidan</surname><given-names>M</given-names></name>, <name><surname>Baskaran</surname><given-names>A</given-names></name> (<year>2013</year>) <article-title>Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions</article-title>. <source>Depress Anxiety</source><volume>30</volume>:<fpage>515</fpage>&#x02013;<lpage>527</lpage><pub-id pub-id-type="pmid">23468126</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal"><name><surname>M&#x000f8;rk</surname><given-names>A</given-names></name>, <name><surname>Pehrson</surname><given-names>A</given-names></name>, <name><surname>Brennum</surname><given-names>LT</given-names></name>, <name><surname>Nielsen</surname><given-names>SM</given-names></name>, <name><surname>Zhong</surname><given-names>H</given-names></name>, <name><surname>Lassen</surname><given-names>AB</given-names></name>, <name><surname>Miller</surname><given-names>S</given-names></name>, <name><surname>Westrich</surname><given-names>L</given-names></name>, <name><surname>Boyle</surname><given-names>NJ</given-names></name>, <name><surname>Sanchez</surname><given-names>C</given-names></name>, <name><surname>Fischer</surname><given-names>CW</given-names></name>, <name><surname>Liebenberg</surname><given-names>N</given-names></name>, <name><surname>Wegener</surname><given-names>G</given-names></name>, <name><surname>Bundgaard</surname><given-names>C</given-names></name>, <name><surname>Hogg</surname><given-names>S</given-names></name>, <name><surname>Bang-Andersen</surname><given-names>B</given-names></name>, <name><surname>Stensbol</surname><given-names>TB</given-names></name> (<year>2012</year>) <article-title>Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder</article-title>. <source>J Pharm Exp Ther</source><volume>340</volume>:<fpage>666</fpage>&#x02013;<lpage>675</lpage></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal"><name><surname>M&#x000f8;rk</surname><given-names>A</given-names></name>, <name><surname>Montezinho</surname><given-names>LP</given-names></name>, <name><surname>Miller</surname><given-names>S</given-names></name>, <name><surname>Trippodi-Murphy</surname><given-names>C</given-names></name>, <name><surname>Plath</surname><given-names>N</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Gulinello</surname><given-names>M</given-names></name>, <name><surname>Sanchez</surname><given-names>C</given-names></name> (<year>2013</year>) <article-title>Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats</article-title>. <source>Pharmacol Biochem Behav</source><volume>105</volume>:<fpage>41</fpage>&#x02013;<lpage>50</lpage><pub-id pub-id-type="pmid">23380522</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal"><name><surname>Murrough</surname><given-names>JW</given-names></name>, <name><surname>Henry</surname><given-names>S</given-names></name>, <name><surname>Hu</surname><given-names>J</given-names></name>, <name><surname>Gallezot</surname><given-names>JD</given-names></name>, <name><surname>Planeta-Wilson</surname><given-names>B</given-names></name>, <name><surname>Neumaier</surname><given-names>JF</given-names></name>, <name><surname>Neumeister</surname><given-names>A</given-names></name> (<year>2011</year>) <article-title>Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder</article-title>. <source>Psychopharmacology (Berl)</source><volume>213</volume>:<fpage>547</fpage>&#x02013;<lpage>553</lpage><pub-id pub-id-type="pmid">20480149</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal"><name><surname>Naismith</surname><given-names>SL</given-names></name>, <name><surname>Longley</surname><given-names>WA</given-names></name>, <name><surname>Scott</surname><given-names>EM</given-names></name>, <name><surname>Hickie</surname><given-names>IB</given-names></name> (<year>2007</year>) <article-title>Disability in major depression related to self-rated and objectively-measured cognitive deficits: a preliminary study</article-title>. <source>BMC Psychiatry</source><volume>7</volume>:<fpage>32</fpage><pub-id pub-id-type="pmid">17634111</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal"><name><surname>Pehrson</surname><given-names>AL</given-names></name>, <name><surname>Sanchez</surname><given-names>C</given-names></name> (<year>2013</year>) <article-title>Serotonergic modulation of the glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction</article-title>. <source>CNS Spectr</source> Aug <volume>1</volume>:<fpage>1</fpage>&#x02013;<lpage>13</lpage>. doi: <pub-id pub-id-type="doi">10.1017/S1092852913000540</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal"><name><surname>Pehrson</surname><given-names>AL</given-names></name>, <name><surname>Cremers</surname><given-names>T</given-names></name>, <name><surname>B&#x000e9;try</surname><given-names>C</given-names></name>, <name><surname>van der Hart</surname><given-names>MGC</given-names></name>, <name><surname>J&#x000f8;rgensen</surname><given-names>L</given-names></name>, <name><surname>Madsen</surname><given-names>M</given-names></name>, <name><surname>Haddjeri</surname><given-names>N</given-names></name>, <name><surname>Ebert</surname><given-names>B</given-names></name>, <name><surname>Sanchez</surname><given-names>C</given-names></name> (<year>2013</year>a) <article-title>Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters &#x02013; a rat microdialysis and electrophysiology study</article-title>. <source>Eur Neuropsychopharmacol</source><volume>23</volume>:<fpage>133</fpage>&#x02013;<lpage>145</lpage><pub-id pub-id-type="pmid">22612991</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal"><name><surname>Pehrson</surname><given-names>AL</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Haddjeri</surname><given-names>N</given-names></name>, <name><surname>Gulinello</surname><given-names>M</given-names></name>, <name><surname>Sanchez</surname><given-names>C</given-names></name> (<year>2013</year>b) <article-title>Vortioxetine, a novel multimodal antidepressant, modulates GABA and glutamate neurotransmission via serotonergic mechanisms</article-title>. <source>Eur Neuropsychopharm</source><volume>23</volume> (<issue>Suppl. 2</issue>):<fpage>S196</fpage>&#x02013;<lpage>S197</lpage></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal"><name><surname>Porter</surname><given-names>RJ</given-names></name>, <name><surname>Bourke</surname><given-names>C</given-names></name>, <name><surname>Gallagher</surname><given-names>P</given-names></name> (<year>2007</year>) <article-title>Neuropsychological impairment in major depression: its nature, origin and clinical significance</article-title>. <source>Aust NZ J Psychiatry</source><volume>41</volume>:<fpage>115</fpage>&#x02013;<lpage>128</lpage></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal"><name><surname>Raskin</surname><given-names>J</given-names></name>, <name><surname>Wiltse</surname><given-names>CG</given-names></name>, <name><surname>Siegal</surname><given-names>A</given-names></name>, <name><surname>Sheikh</surname><given-names>J</given-names></name>, <name><surname>Xu</surname><given-names>J</given-names></name>, <name><surname>Dinkel</surname><given-names>JJ</given-names></name>, <name><surname>Rotz</surname><given-names>BT</given-names></name>, <name><surname>Mohs</surname><given-names>RC</given-names></name> (<year>2007</year>) <article-title>Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial</article-title>. <source>Am J Psychiatry</source><volume>164</volume>:<fpage>900</fpage>&#x02013;<lpage>909</lpage><pub-id pub-id-type="pmid">17541049</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal"><name><surname>Rock</surname><given-names>PL</given-names></name>, <name><surname>Roiser</surname><given-names>JP</given-names></name>, <name><surname>Riedel</surname><given-names>WJ</given-names></name>, <name><surname>Blackwell</surname><given-names>AD</given-names></name> (<year>2013</year>) <article-title>Cognitive impairment in depression: a systematic review and meta-analysis</article-title>. <source>Psychol Med</source><fpage>1</fpage>&#x02013;<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.1017/S0033291713002535</pub-id><pub-id pub-id-type="pmid">24168753</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal"><name><surname>Rockwood</surname><given-names>K</given-names></name> (<year>2004</year>) <article-title>Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease</article-title>. <source>J Neurol Neurosurg Psychiatry</source><volume>75</volume>:<fpage>677</fpage>&#x02013;<lpage>685</lpage><pub-id pub-id-type="pmid">15090558</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal"><name><surname>Rund</surname><given-names>BR</given-names></name>, <name><surname>Sundet</surname><given-names>K</given-names></name>, <name><surname>Asbjornsen</surname><given-names>A</given-names></name>, <name><surname>Egeland</surname><given-names>J</given-names></name>, <name><surname>Landro</surname><given-names>NI</given-names></name>, <name><surname>Lund</surname><given-names>A</given-names></name>, <name><surname>Roness</surname><given-names>A</given-names></name>, <name><surname>Stordal</surname><given-names>KI</given-names></name>, <name><surname>Hugdahl</surname><given-names>K</given-names></name> (<year>2006</year>) <article-title>Neuropsychological test profiles in schizophrenia and non-psychotic depression</article-title>. <source>Acta Psychiatr Scand</source><volume>113</volume>:<fpage>350</fpage>&#x02013;<lpage>359</lpage><pub-id pub-id-type="pmid">16638080</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal"><name><surname>Sanchez</surname><given-names>C</given-names></name>, <name><surname>Robichaud</surname><given-names>PJ</given-names></name>, <name><surname>Pehrson</surname><given-names>A</given-names></name>, <name><surname>Leiser</surname><given-names>SC</given-names></name> (<year>2012</year>) <article-title>The effects of the multimodal antidepressant Lu AA21004 on attention and vigilance measured as EEG activity in the rat</article-title>. <source>Eur Neuropsychopharmacol</source><volume>22</volume> (<issue>Suppl. 2</issue>):<fpage>S243</fpage>&#x02013;<lpage>S244</lpage></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal"><name><surname>Streiner</surname><given-names>DL</given-names></name> (<year>2005</year>) <article-title>Finding our way: an introduction to path analysis</article-title>. <source>Can J Psychiatry</source><volume>50</volume>:<fpage>115</fpage>&#x02013;<lpage>122</lpage><pub-id pub-id-type="pmid">15807228</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal"><name><surname>Svendsen</surname><given-names>AM</given-names></name>, <name><surname>Kessing</surname><given-names>LV</given-names></name>, <name><surname>Munkholm</surname><given-names>K</given-names></name>, <name><surname>Vinberg</surname><given-names>M</given-names></name>, <name><surname>Miskowiak</surname><given-names>KW</given-names></name> (<year>2012</year>) <article-title>Is there an association between subjective and objective measures of cognitive function in patients with affective disorders?</article-title><source>Nord J Psychiatry</source><volume>66</volume>:<fpage>248</fpage>&#x02013;<lpage>253</lpage><pub-id pub-id-type="pmid">22070515</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="other"><collab>United States Food and Drug Administration (FDA)</collab> (<year>2010</year>) Guidance for industry: suicidality: prospective assessment of occurrence in clinical trials, September 2010. <uri xlink:type="simple" xlink:href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm315156.htm">http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm315156.htm</uri></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal"><name><surname>Westrich</surname><given-names>L</given-names></name>, <name><surname>Pehrson</surname><given-names>A</given-names></name>, <name><surname>Zhong</surname><given-names>H</given-names></name>, <name><surname>Nielsen</surname><given-names>SM</given-names></name>, <name><surname>Frederiksen</surname><given-names>K</given-names></name>, <name><surname>Stensb&#x000f8;l</surname><given-names>TB</given-names></name>, <name><surname>Boyle</surname><given-names>N</given-names></name>, <name><surname>Hentzer</surname><given-names>M</given-names></name>, <name><surname>Sanchez</surname><given-names>C</given-names></name> (<year>2012</year>) <article-title><italic>In vitro</italic> and <italic>in vivo</italic> effects of the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets</article-title>. <source>Int J Psychiatry Clin Pract</source><volume>16</volume> (<issue>Suppl. 1</issue>):<fpage>47</fpage></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="other"><collab>World Medical Association (WMA)</collab> (<year>2008</year>) Declaration of Helsinki: ethical principles for medical research involving human subjects. <uri xlink:type="simple" xlink:href="http://www.wma.net/en/30publications/10policies/b3/">http://www.wma.net/en/30publications/10policies/b3/</uri></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal"><name><surname>Zimmerman</surname><given-names>M</given-names></name>, <name><surname>McGlinchey</surname><given-names>JB</given-names></name>, <name><surname>Posternak</surname><given-names>MA</given-names></name>, <name><surname>Friedman</surname><given-names>M</given-names></name>, <name><surname>Boerescu</surname><given-names>D</given-names></name>, <name><surname>Attiullah</surname><given-names>N</given-names></name> (<year>2008</year>) <article-title>Remission in depressed outpatients: more than just symptom resolution?</article-title><source>J Psychiatr Res</source><volume>42</volume>:<fpage>797</fpage>&#x02013;<lpage>801</lpage><pub-id pub-id-type="pmid">17986389</pub-id></mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal"><name><surname>Zimmerman</surname><given-names>M</given-names></name>, <name><surname>Martinez</surname><given-names>J</given-names></name>, <name><surname>Attiullah</surname><given-names>N</given-names></name>, <name><surname>Friedman</surname><given-names>M</given-names></name>, <name><surname>Toba</surname><given-names>C</given-names></name>, <name><surname>Boerescu</surname><given-names>DA</given-names></name> (<year>2012</year>) <article-title>Why do some depressed outpatients who are not in remission according to the Hamilton depression rating scale nonetheless consider themselves to be in remission?</article-title><source>Depress Anxiety</source><volume>29</volume>:<fpage>891</fpage>&#x02013;<lpage>895</lpage><pub-id pub-id-type="pmid">22887476</pub-id></mixed-citation></ref></ref-list></back></article>